Payment overview · 2025
General Payments
$621.21
30 reported records · 14 companies
Healthcare provider profile · identity verified
Malcolm B. Oliver, MD
Allopathic & Osteopathic Physicians|Family Medicine · GREENFIELD, MO · NPI 1730278730
Verified facts
What the public records show
CMS Open Payments records show Malcolm B. Oliver, MD received $621.21 in general payments during 2025 across 30 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 22.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rexulti, Rybelsus.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 253 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $140.13 | 22.6% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $74.28 | 12.0% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $54.28 | 8.7% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $54.04 | 8.7% | 3 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $49.63 | 8.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $38.95 | 6.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $34.38 | 5.5% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $33.57 | 5.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.32 | 5.0% | 2 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $23.81 | 3.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.56 | 3.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $23.35 | 3.8% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.87 | 3.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.04 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $621.21 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $157.17 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $56.55 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $54.28 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $54.04 | 3 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $49.63 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $38.95 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $36.40 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $34.38 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $34.38 | 2 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $33.57 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $32.35 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $31.32 | 2 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $23.81 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $23.56 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $23.35 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.87 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 124 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
178 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
84 | 11 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
124 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
253 | 35 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1332 | 168 |
| Atorvastatin Calcium | Atorvastatin Calcium | 880 | 144 |
| Gabapentin | Gabapentin | 758 | 107 |
| Levothyroxine Sodium | Levothyroxine Sodium | 601 | 87 |
| Lisinopril | Lisinopril | 588 | 112 |
| Amlodipine Besylate | Amlodipine Besylate | 523 | 95 |
| Furosemide | Furosemide | 519 | 83 |
| Metformin Hcl | Metformin Hcl | 501 | 79 |
| Omeprazole | Omeprazole | 467 | 76 |
| Potassium Chloride | Potassium Chloride | 430 | 83 |
| Duloxetine Hcl | Duloxetine Hcl | 400 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 389 | 62 |
| Trazodone Hcl | Trazodone Hcl | 354 | 54 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 350 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 340 | 60 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 328 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 328 | 51 |
| Tramadol Hcl | Tramadol Hcl | 318 | 60 |
| Citalopram Hbr | Citalopram Hydrobromide | 307 | 52 |
| Lorazepam | Lorazepam | 306 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 302 | 52 |
| Oxycodone Hcl | Oxycodone Hcl | 300 | 41 |
| Losartan Potassium | Losartan Potassium | 276 | 44 |
| Baclofen | Baclofen | 271 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 256 | 36 |
| Eliquis | Apixaban | 253 | 35 |
| Morphine Sulfate Er | Morphine Sulfate | 248 | 25 |
| Pregabalin | Pregabalin | 239 | 32 |
| Clonazepam | Clonazepam | 235 | 24 |
| Buspirone Hcl | Buspirone Hcl | 220 | 35 |
| Sertraline Hcl | Sertraline Hcl | 220 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 219 | 35 |
| Alprazolam | Alprazolam | 217 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 214 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 204 | 30 |
| Meloxicam | Meloxicam | 193 | 41 |
| Ropinirole Hcl | Ropinirole Hcl | 188 | 28 |
| Jardiance | Empagliflozin | 178 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 177 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 171 | 22 |
| Montelukast Sodium | Montelukast Sodium | 170 | 21 |
| Mirtazapine | Mirtazapine | 164 | 27 |
| Carvedilol | Carvedilol | 163 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 163 | 26 |
| Spironolactone | Spironolactone | 161 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 154 | 31 |
| Donepezil Hcl | Donepezil Hcl | 152 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 142 | 28 |
| Glimepiride | Glimepiride | 140 | 25 |
| Diazepam | Diazepam | 127 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 124 | 21 |
| Metformin Hcl Er | Metformin Hcl | 124 | 24 |
| Ozempic | Semaglutide | 124 | 21 |
| Finasteride | Finasteride | 122 | 16 |
| Celecoxib | Celecoxib | 108 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 108 | 29 |
| Testosterone Cypionate | Testosterone Cypionate | 108 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 106 | 15 |
| Estradiol | Estradiol | 104 | 17 |
| Simvastatin | Simvastatin | 104 | 21 |
| Atenolol | Atenolol | 103 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 103 | 20 |
| Aripiprazole | Aripiprazole | 95 | 15 |
| Famotidine | Famotidine | 94 | 16 |
| Lovastatin | Lovastatin | 93 | 13 |
| Hydromorphone Hcl | Hydromorphone Hcl | 92 | 11 |
| Glipizide Er | Glipizide | 90 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 89 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 88 | 32 |
| Januvia | Sitagliptin Phosphate | 86 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 85 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 85 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 85 | 15 |
| Allopurinol | Allopurinol | 84 | 14 |
| Trulicity | Dulaglutide | 84 | 11 |
| Alendronate Sodium | Alendronate Sodium | 82 | 15 |
| Xarelto | Rivaroxaban | 80 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 77 | 31 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 76 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 74 | 16 |
| Ezetimibe | Ezetimibe | 72 | 13 |
| Memantine Hcl | Memantine Hcl | 68 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 67 | suppressed |
| Bupropion Xl | Bupropion Hcl | 65 | 16 |
| Ibuprofen | Ibuprofen | 63 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 63 | suppressed |
| Entresto | Sacubitril/Valsartan | 61 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 61 | suppressed |
| Prednisone | Prednisone | 60 | 18 |
| Topiramate | Topiramate | 60 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 57 | suppressed |
| Glipizide | Glipizide | 55 | 11 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 53 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 12 |
| Chlorthalidone | Chlorthalidone | 51 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 51 | suppressed |
| Bumetanide | Bumetanide | 50 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 50 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | 12 |
| Linzess | Linaclotide | 49 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 48 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 48 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 47 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 38 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 46 | suppressed |
| Klor-Con M20 | Potassium Chloride | 46 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 45 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 44 | 34 |
| Myrbetriq | Mirabegron | 43 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 41 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 40 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 39 | suppressed |
| Nystatin | Nystatin | 39 | 18 |
| Risperidone | Risperidone | 39 | suppressed |
| Azithromycin | Azithromycin | 38 | 38 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 21 |
| Gemfibrozil | Gemfibrozil | 38 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Ondansetron Odt | Ondansetron | 38 | 18 |
| Breo Ellipta | Fluticasone/Vilanterol | 37 | suppressed |
| Ketoconazole | Ketoconazole | 37 | suppressed |
| Verapamil Er | Verapamil Hcl | 37 | suppressed |
| Westab Plus | Pnv,calcium 72/Iron/Folic Acid | 35 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 32 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 32 | suppressed |
| Naproxen | Naproxen | 31 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 30 | suppressed |
| Belsomra | Suvorexant | 30 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Rexulti | Brexpiprazole | 30 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 30 | 19 |
| Carbamazepine Er | Carbamazepine | 29 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Lidocaine | Lidocaine | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | suppressed |
| Lamotrigine | Lamotrigine | 27 | suppressed |
| Oxycontin | Oxycodone Hcl | 27 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 27 | suppressed |
| Loperamide | Loperamide Hcl | 26 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 26 | suppressed |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 26 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 25 |
| Primidone | Primidone | 25 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 24 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 24 | suppressed |
| Latanoprost | Latanoprost | 24 | suppressed |
| Multaq | Dronedarone Hcl | 24 | suppressed |
| Thiothixene | Thiothixene | 24 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 24 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 23 | suppressed |
| Olanzapine | Olanzapine | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 12 |
| Xtampza Er | Oxycodone Myristate | 23 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 22 | suppressed |
| Modafinil | Modafinil | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Cilostazol | Cilostazol | 21 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 21 | suppressed |
| Fentanyl | Fentanyl | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Mupirocin | Mupirocin | 18 | 11 |
| Atrovent Hfa | Ipratropium Bromide | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 14 |
| Minocycline Hcl | Minocycline Hcl | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 15 |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 16 | 16 |
| Breyna | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Cefdinir | Cefdinir | 15 | 14 |
| Diclofenac Potassium | Diclofenac Potassium | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 11 |
| Glyburide | Glyburide | 14 | suppressed |
| Klor-Con M10 | Potassium Chloride | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Renvela | Sevelamer Carbonate | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Paliperidone Er | Paliperidone | 13 | suppressed |
| Restasis | Cyclosporine | 13 | suppressed |
| Risperidone Odt | Risperidone | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Topamax | Topiramate | 13 | suppressed |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
| Rybelsus | Semaglutide | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Triazolam | Triazolam | 11 | suppressed |
| Trospium Chloride | Trospium Chloride | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $621.21 · 30 records | Otsuka America Pharmaceutical, Inc. | AIRSUPRA, BREZTRI, CAPLYTA, Cologuard Collection Kit, GVOKE HYPOPEN, ImmunoCAP, MOUNJARO, NURTEC ODT, Ozempic, PAXLOVID, Quviviq, REXULTI, Rybelsus, Senza, Veozah, XIFAXAN, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error